Wong S, Rosenthal M A, deBoer R, Green M D, Fox R M
Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Intern Med J. 2004 Aug;34(8):458-63. doi: 10.1111/j.1445-5994.2004.00636.x.
The management of patients with metastatic non-small cell lung cancer (NSCLC) is complex. Some studies have demonstrated that the care of patients with NSCLC may be suboptimal.
To review the management of patients with metastatic NSCLC treated at a single teaching hospital over a 5-year period.
All patients with metastatic NSCLC treated at a single teaching hospital over a 5-year period (1998-2002) were identified. Data were collected by a retrospective record review.
Of 343 patients with metastatic NSCLC, 157 patients were deemed eligible for this review. Thirty-one patients (19%) were admitted to the Medical Oncology Unit at initial presentation. Twenty-four patients (15%) were not referred to either the Medical Oncology Unit or the Palliative Care Unit. Forty-four patients (28%) received chemotherapy, six of whom (14%) were enrolled onto a clinical trial. Six separate chemotherapy regimens were used. The median survival was 5 months and the 1-year survival rate was 19.8%.
The present audit demonstrates some shortfalls in the optimal clinical care of patients with metastatic NSCLC at a large teaching hospital. The main selection criteria of consideration for chemotherapy are age, performance status and presence of symptoms. A subset of patients was not referred to either the Medical Oncology Unit or the Palliative Care Unit and consistency in the choice of chemotherapy was lacking. Survival data and the rate of patients entered onto clinical trials are acceptable; however, further improvements can be made by the institution of multidisciplinary clinics and the education of referring clinicians.
转移性非小细胞肺癌(NSCLC)患者的管理较为复杂。一些研究表明,NSCLC患者的护理可能并不理想。
回顾一家教学医院5年间对转移性NSCLC患者的管理情况。
确定一家教学医院5年间(1998 - 2002年)收治的所有转移性NSCLC患者。通过回顾性病历审查收集数据。
在343例转移性NSCLC患者中,157例被认为符合本研究标准。31例患者(19%)初诊时入住肿瘤内科。24例患者(15%)未被转诊至肿瘤内科或姑息治疗科。44例患者(28%)接受了化疗,其中6例(14%)参加了临床试验。使用了6种不同的化疗方案。中位生存期为5个月,1年生存率为19.8%。
本次审计表明,一家大型教学医院在转移性NSCLC患者的最佳临床护理方面存在一些不足。考虑化疗的主要选择标准是年龄、体能状态和症状的存在。一部分患者未被转诊至肿瘤内科或姑息治疗科,且化疗方案的选择缺乏一致性。生存数据和参加临床试验的患者比例是可以接受的;然而,通过设立多学科门诊和对转诊临床医生进行教育可以进一步改善。